June 25, 2019
The US FDA has turned down Daiichi Sankyo’s FLT3 inhibitor quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), the company said on June 21, just three days after the drug won approval on the...read more